Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2A | Q12879 | 1/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.53 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.53 |
| ▸ | CCR3 | P51677 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7025586 | 0.86 | HTR2A (0.52) | GRIN2BHTR2AHTR2C | |
| SCHEMBL4872002 | 0.86 | ACHE (0.57) | GRIN2AGRIN2BACHECARM1PRMT6 | |
| SCHEMBL6875117 | 0.84 | SIGMAR1 (0.49) | GRIN2AGRIN2B | |
| SCHEMBL6875081 | 0.83 | SIGMAR1 (0.50) | GRIN2BCCR3CYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL6873860 | 0.83 | SIGMAR1 (0.48) | GRIN2AGRIN2B | |
| SCHEMBL6880262 | 0.83 | SIGMAR1 (0.50) | GRIN2BCCR3CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6874312 | 0.83 | SIGMAR1 (0.50) | GRIN2BCCR3CYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL6884566 | 0.82 | SIGMAR1 (0.49) | GRIN2BCCR3CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4865285 | 0.81 | CARM1 (0.49) | GRIN2AGRIN2BCARM1PRMT6 | |
| SCHEMBL7032512 | 0.81 | CARM1 (0.57) | ACHECARM1PRMT6HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7408067-B2 | Aza-cyclic compounds as modulators of acetylcholine receptors | MERCK + CO., INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-20050070520-A1 | Aza-cyclic compounds as modulators of acetylcholine receptors | MERCK SHARP & DOHME CORP. | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070520-A1 | Aza-cyclic compounds as modulators of acetylcholine receptors | CHRNG, CHRNA4, CHRNB4 | GRIN2A 204/4885GRIN2B 199/4885ACHE 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.